Essetifin SPA's Form 4 filing
Regenerx Biopharmaceuticals Inc (RGRX) · filed Jul 6, 2023
- Accession no.
- 0001213900-23-055186
- Filed
- Jul 6, 2023, 4:30 PM ET
- Trade date
- Jul 3, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 derivative transactions. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Essetifin SPACIK 0001092601 | 10% Owner |
| Cavazza PaoloCIK 0001163608 | 10% Owner |
| Aptafin S P ACIK 0001232942 | Other: Member of 10% owner group |
| Cavazza FrancescaCIK 0001525742 | 10% Owner |
| Cavazza SilviaCIK 0001525743 | 10% Owner |
| Cavazza EnricoCIK 0001525744 | 10% Owner |
| Cavazza Preta MartinaCIK 0001718557 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F7
On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the "2023 Agreement"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the "2023 Note") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the "2023 Warrant").
Referenced by the price of 2 transactions in Table II.
- F8
The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion.
Referenced by the price of 1 transaction in Table II.
- F9
The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date.
Referenced by the price of 1 transaction in Table II.